Angelini Ventures backs Nouscom’s €120 million Series D round

• Nouscom raised €120 million in an oversubscribed Series D with backing from Angelini Ventures, an investor since Series C.
• M Ventures and Revelation Partners co-led the round. The European Investment Bank participated through a co-investment facility.
• The clinical-stage biotech develops immunotherapies that train the immune system to intercept cancer at its earliest stages.
• Proceeds will fund a global registration-enabling trial of NOUS-209, its off-the-shelf neoantigen-based immunotherapy, in Lynch syndrome.
• NOUS-209 holds FDA Fast Track designation for this indication. Long-term Phase 1b/2 data will be presented October 25 at ESMO in Madrid.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Angelini Ventures SpA published the original content used to generate this news brief on October 19, 2026, and is solely responsible for the information contained therein.